ALX ONCOLOGY HOLDINGS INC (ALXO)
About ALX ONCOLOGY HOLDINGS INC
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $0
- Net income
- -$101.7M
- Total assets
- $59.0M
- Market cap
- $207.2M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $104.0M
- Operating income
- -$104.0M
- Income tax
- $0
- Net income
- -$101.7M
- EPS (basic)
- $-1.90
- EPS (diluted)
- $-1.90
Balance sheet
- Total assets
- $59.0M
- Current assets
- $50.7M
- Total liabilities
- $33.1M
- Current liabilities
- $24.6M
- Shareholders’ equity
- $26.0M
Cash flow
- Operating cash flow
- -$84.1M
- Investing cash flow
- $82.6M
- Financing cash flow
- $362.0K
- Net cash flow
- -$1.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $207.2M
- EPS (diluted)
- $-1.9
- Shares outstanding
- 102.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 17, 2020
ALX Oncology Holdings Inc (ALXO) Stock Price
- Reported a net loss of $101.7M in FY2022.
- Trading 22% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ALX ONCOLOGY HOLDINGS INC.
Write a review
News about ALX ONCOLOGY HOLDINGS INC
News & sentiment via Polygon.io
ALX Oncology Holdings Inc: frequently asked questions
Is ALX Oncology Holdings Inc an American company?
ALX Oncology Holdings Inc is a US-based company headquartered in South San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is ALX Oncology Holdings Inc headquartered?
ALX Oncology Holdings Inc is headquartered in South San Francisco, California, United States.
Is ALX Oncology Holdings Inc publicly traded?
Yes — ALX Oncology Holdings Inc is a publicly traded company. Its stock trades under the ticker symbol ALXO on the NASDAQ.
What does ALX Oncology Holdings Inc do?
ALX Oncology Holdings Inc is an American Pharmaceuticals company in the Health & Beauty sector.
